> 9.1 > 9.1 > 9.1 > 9.1 PI3Kβ > 9.1 > 9.1 > 9.1 > 9.1 PI4Kβ > 9.1 > 9.1 > 9.1 > 9.1 VPS34 > 9.1 > 9.1 > 9.1 > 9.1 ADP-FRET PIK3CD > 9.1 > 9.1 > 9.1 > 9.1 ADP-FRET PIK3CG > 9.1 > 9.1 > 9.1 > 9. 1   Table S1 . The compound 5'carboxy-7-bromoindirubin 3'-oxime 6i and its N1-Me analogue 6l were assayed in a panel of 42 protein kinases along with 6BIO and 7BIO
and their specificity profile was evaluated.
Data Collection PDB ID 3KVW
Ligand 6i
Space group P4 2 
Chemistry

Synthesis of the targeted derivatives
In an effort to prepare derivatives consistent with the rationale, we synthesized a range of 7-BIO derivatives bearing carboxymethyl, carboxylic acid, aldehyde, methylenehydroxy, oxime, cyano and tetrazole moieties on the 5'-and 6'-positions.
The same derivatizations were also applied to the new 7-(trifluoromethyl)-indirubin series by replacing the bromine by a trifluoromethyl group. The synthesis of 7-monosubstituted, 7,5'-or 7,6'-bisubstituted indirubins was based on the dimerization reaction of an appropriately 7-substituted isatin derivative and the 3-acetoxy-5-or 6-substituted indole as depicted in Schemes S1 and S2 except in the case of 7-bromo-5'-hydroxymethyl-indirubin 5n and the 7-bromo-5'-oxime-indirubin 5o which were prepared from the 7-bromo-5'-formyl-indirubin 5q. The 7-(trifluoromethyl)-5'-tetrazolo-indirubin 5g was prepared from 7-(trifluoromethyl)-5'-cyano-indirubin 5f.
The procedures are described further.
The desired 7-bromo-and 7-trifluoromethyl-isatins 3a and 3b were synthesized in a two-steps procedure using the corresponding commercial 7-bromoand 7-trifluoromethyl-aniline 1a-1b as starting material. In the first step, anilines were converted to the corresponding isonitrosoacetanilides 2a-2b.
1,2
The latter underwent cyclisation in warm concentrated sulfuric acid to give the expected isatins in good yields. The 7-bromo-N-methylisatin 4a was obtained by methylation of 7-bromoisatin 3a using dimethylsulfate. Isatins 3a-3b and 4a were then engaged in coupling reaction with the commercially available 3-acetoxyindole to give in good yields indirubins 5a, 7BI and 7TFI (Scheme S1)
The 3-acetoxy-5-or 6-substituted indoles 9a-9d were prepared from the corresponding commercial 5-or 6-substituted indoles 7a-7d in a two-step procedure. 3 After introduction of iodine on the 3-position the halogen was converted in acetoxy group by the action of silver acetate in hot acetic acid. The corresponding acetoxyindoles were obtained in moderate yields (Scheme S2). The substituted isatins 3a-3b, 7-bromo-N-methylisatin 4a and commercially available isatin were reacted with the 3-acetoxyindoles 9a-9d in alkaline medium to give in good yields the corresponding bis-indoles 5b, 5d-5f, 5h, 5j-5k and 5p selectively in Z form. (Scheme S2). The oximes 7BIO, 6a-6b, 6c, 6e-6h, 6k, 6n-6o, 6r-6s were prepared selectively in a (2'Z,3'E) form by action of hydroxylamine hydrochloride in refluxing pyridine (Scheme S2).
4
The 7-bromo-5'-formyl-indirubin 5r was obtained by acidic hydrolysis of the 7-bromo-5'-(dimethoxyacetal)-indirubin 5q formed during the dimerization due to the alkaline methanolic conditions. This 5'-formyl function was reacted with hydroxylamine hydrochloride under specific solvent conditions (CH 3 CN/MeOH) in order to form only the 7-bromo-5'-oxime-indirubin 5o without affect the carbonyl in 3'-position. The 7-bromo-5'-formyl-indirubin 5q was also engaged in a selective reduction by action of NaBH 4 in THF to give the 7-bromo-5'-hydroxymethylindirubin 5n (Scheme S2). 7-(trifluoromethyl)-5'-tetrazolo-indirubin 5g was prepared by the condensation of trimethylsilyl azide on the 7-(trifluoromethyl)-5'-cyanoindirubin 5f in presence of tetrabutlyammonium fluoride as a catalyst in refluxing pyridine. The corresponding 1H-tetrazolo-indirubin was obtained with 70% yield (Scheme S2).
5
The carboxylic acids were deprotected by using a solution of sodium hydroxide 1N in THF/MeOH at 65°C for 24h. The following acidification using a solution of hydrochloric acid 1N led to the final compounds in good yields (Scheme S2). 
General Procedure for the Preparation of Isatins (3a-3b)
In a three-neck round bottom flask was added the aniline 1a-1b (32.1mmol, 3.5mL).
Then a warm diluted solution of concentrated HCl (3.5mL) in warm water (23mL), a solution of chloralhydrate (35.1mmol, 5.8g) and Na 2 SO 4 (126mmol, 17.9g) in warm water (81mL) were added, followed by a solution of hydroxylamine (102mmol, 7.09 g) in warm water (32mL). The mixture was stirred at 80-90°C for 2h. The mixture was then allowed to cool for 1h, by which time the temperature had fallen to 50°C and filtered. The brown-product was washed by stirring with water (500mL) and filtered (2a). Drying for 3-4 days at 40°C gave the corresponding isonitrosoacetanilide 2a. In the case of 2b, the compound was extracted three times with CH 2 Cl 2 , the organic phases gathered, dried with anhydrous Na 2 SO 4 and evaporated under vacuum to afford the corresponding isonitrosoacetanilide 2b as amber oil.
Sulfuric acid (15mL) was heated in a two-neck round bottom flask to 60°C
and then removed. The dry isonitrosoacetanilide 2a-2b was added in portions with stirring over 30 min so that the temperature did not exceed 65°C. The mixture was then heated to 80°C for 15min, allowed to cool to 70°C and cooled on ice. The solution was poured onto crushed ice and left to stand for 1h before the orange-red precipitate was filtered to give the corresponding isatin 3a (65%) and 3b (25%). The data analyses were conformed to literature.
Preparation of the 1-N-methyl-7-bromo-isatin (4a)
The compound 4a was prepared as described before.
1
General Procedure for the Preparation of the 3-acetoxyindoles
The 5-or 6-substituted-indole was dissolved in methanol (20mL). Then NaOH (1eq), I 2 (1eq) were added, followed by a solution of KI (1eq) in water (1mL). The flask was covered from light and the mixture was strongly stirred at room temperature for 3h.
Then water (20mL) was added and the white cream product was filtered, washed with water (100mL), protected from light and dried in a dessicator at 40°C for 2h. The 
General Procedure for the Preparation of (2'Z)-Indirubins
Methanol (15mL) was vigorously stirred under nitrogen for 20min, and the desired isatin and 3-acetoxyindole (0.8eq) were added. The mixture was stirred for 5min then anhydrous Na 2 CO 3 (1.1eq) was added and the stirring was continued for 3h30 at room temperature. Water (60mL) was added and the purple precipitate was filtered, washed with aqueous methanol (1:1) and with water to give corresponding indirubin selectively in the Z form.
Data for the (2'Z)-7-bromo-indirubin (7BI).
The data were conformed to literature. Procedure for the preparation of (2'Z)-7-bromo-5'-hydroxymethyl-indirubin (5n). To a solution of the formylated compound 5r (0.25 mmol) in THF (10 mL), NaBH 4 (38 mg, 0.37 mmol) was added and the mixture was stirred for 15 min at room temperature using an output in order for the excess of the produced H 2 to be evacuated. 1 mL of CH 3 COOH was added afterwards and the resulting mixture was evaporated using a high vacuum pump. Water (50 mL) was added and filtration, washing with H 2 O, Chex and CH 2 Cl 2 and drying gave 5n (90% yield). 
Data for the (2'Z)-1-N-methyl-7-bromo-indirubin (5a
Data for (2'Z)-1-N-methyl-7-bromo-5'-carboxymethylester-indirubin (5h
General Procedure for the Preparation of the Oximes
The appropriate indirubin derivative (1mmol) was dissolved in pyridine (10mL). With magnetic stirring hydroxylamine hydrochloride (10eq) was added and the mixture was heated under reflux (120°C) for 1.5h. Then water was added (30mL) and the red precipitate was filtered, washed with a 1% HCl solution to remove the pyridine and well washed with water (150mL) to afford quantitatively the corresponding 3'-oxime selectively in the (2'Z,3'E) form.
Data for (2'Z,3'E)-7-bromo-3'-oxim-indirubin (7BIO).
The data were conformed to literature. 
Data for (2'Z,3'E)-1-N-methyl-7-bromo-3'-oxim-indirubin (6b).
1
Data for (2'Z,3'E)-3'-oxim-5'-carboxymethylester-indirubin (6c
Data for (2'Z,3'E)-7-bromo-3'-oxim-5'-carboxymethylester-indirubin (6e).
Data for (2'Z,3'E)-7-trifluoromethyl-3'-oxim-5'-carboxymethylester-indirubin (6f).
Data for (2'Z,3'E)-7-trifluoromethyl-3'-oxim-5'-tetrazolo-indirubin (6h
(1H, brt, H-5). MS (ESI-) m/z: 412 (M -
)
Data for (2'Z,3'E)-7-bromo-3'-oxim-6'-carboxymethylester-indirubin (6n
Data for (2'Z,3'E)-7-bromo-3',5'-dioxim-indirubin (6s).
H NMR (DMSO, 400
MHz, δ ppm) 13.75 (1H, brs, NOH), 11.97 (1H, s, N'-H), 11.08 (1H, brs, CHNOH), 
Data for (2'Z,3'E)-7-trifluoromethyl-3'-oxim-5'-carboxylic acid-indirubin (6j).
Yield 100%. The constructs were transformed into competent Mach1™ cells (Invitrogen™, UK) to yield the final plasmid DNA.
Protein Expression and Purification
Colonies from freshly transformed plasmid DNA in competent E. coli BL21 ( (GE/Amersham Biosciences). Samples were monitored by SDS-polyacrylamide gel electrophoresis and concentrated to 7.3 mg/ml in the gel-filtration buffer, 25 mM Hepes pH 7.5, 500 mM NaCl, 0.5 mM TCEP using an Amicon 10 kDa cut-off concentrator and were used for crystallization. Protein handling was carried out on ice or in a cold room in all the above steps.
Crystallization
Aliquots of the purified protein were set up for crystallization using a mosquito® crystallization robot (TTP Labtech, Royston UK). Coarse screens were typically setup onto Greiner 3-well plates using three different drop ratios of precipitant to protein per condition (100+50 nl, 75+75 nl and 50+100 nl). Initial hits were optimized further scaling up the drop sizes. All crystallizations were carried out using the sitting drop vapor diffusion method at 4 °C. DYRK2 crystals with K02510 were grown by mixing 200 nl of the protein (7.3 mg/ml and 1 mM final ligand concentration) with 100 nl of reservoir solution containing 0.20 M NaOAc, 0.1 M cacodylate pH 6.5 and 30 % PEG8000. Diffraction quality crystals grew within a few days and were cryoprotected using the well solution supplemented with 2 M Li 2 SO 4 for structure determination.
Data Collection and Structure solution
Data were collected at Diamond beam-line I03 at a single wavelength of 0.9763 Å.
Indexing and integration was carried out using MOSFLM and scaling was performed with SCALA. 7, 8 Initial phases were calculated by molecular replacement with PHASER using the known model of DYRK2 (PDB ID 3KL2). 9 Initial models were built by ARP/wARP followed by manual building in COOT. 10, 11 Refinement was carried out in REFMAC5. 12 In all cases thermal motions were analyzed using TLSMD and hydrogen atoms were included in late refinement cycles. 13 Data collection and refinement statistics can be found in Supplemental Table X . The model and structure factors has been deposited with PDB accession code 3KVW.
Biochemical assays
Buffers.
Buffer A: 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 µg heparin/ml. CDK5/p25 (human, recombinant) was prepared as previously described.
14 Its kinase activity was assayed in buffer C, with 1 mg histone H1 /ml.
GSK-3α/β (porcine brain, native) was assayed in Buffer A and using a GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated serine).
CK1δ/ε (porcine brain, native) was assayed in three-fold diluted buffer C, using 25 µM CKS peptide (RRKHAAIGpSAYSITA), a CK1-specific substrate.
Theoretical simulations Homology modeling
Homology modeling was performed using MODELLER v.9.8 implementing the loop optimization routine and a slow simulated annealing protocol for refinement.
15
Docking Calculations. 
18,19
The relevant solvation thermodynamic quantities for the ligand are computed based on the amount of overlap with the hydration sites.
